Newron licenses safinamide to Zambon for EU and USA

9 April 2012

Italian drug developer Newron Pharmaceuticals (SIX: NWRN) says that it has signed a strategic collaboration and licence option with privately-held Zambon, also Based in Italy, for its lead compound safinamide, rights to which were returned to Newron last year by Merck Serono and effective April 17 this year (The Pharma Letter October 24, 2011).

The compound is currently in Phase III development as an add-on therapy to dopamine agonists and levodopa in patients with Parkinson’s disease. Under the agreement, Zambon will make an initial investment of 20 million euros ($26.6 million) into Newron as defined below, also covering the completion of safinamide’s clinical development and the preparation of the application for marketing approval in Europe and the USA.

Zambon takes 9.1% equity stake in Newron

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK